We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reactive Oxygen Species May Have Antitumor Activity in Metastatic Melanoma.
- Authors
Tuma, Rabiya S.
- Abstract
The article reports on the results of a clinical trial which showed that elesclomol, an investigational drug that causes cells to produce excess reactive oxygen species (ROS), was associated with long progression-free survival in patients with metastatic melanoma. A description of the clinical trial and measurement methods is provided. A description of elesclomol's mechanism of action is provided.
- Subjects
CLINICAL trials; REACTIVE oxygen species; MELANOMA treatment; CANCER treatment; ANTINEOPLASTIC agents
- Publication
JNCI: Journal of the National Cancer Institute, 2008, Vol 100, Issue 1, p11
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djm299